Lonza has announced it will invest in additional inhalation testing capacity at its Tampa (US) site specialized in development, clinical, and commercial manufacturing of small molecule-based therapies targeting respiratory diseases and disorders, such as cancer, asthma, and chronic obstructive pulmonary disease (COPD).   Building upon Lonza’s extensive expertise and more than 25 years of experience in supporting particle engineering projects from the Bend (US) site, the expansion will establis...